The Complete NHS Vaccination Schedule — Birth to Year 9
The full UK childhood schedule in England. For the detailed clinical guide for any individual appointment, use the age-specific links in the final column.
| Age / Appointment | Vaccines Given | Diseases Covered | Detail Guide |
|---|---|---|---|
| 8 weeks | 6-in-1 (dose 1) · MenB (dose 1) · Rotavirus oral (dose 1) | Diphtheria, tetanus, whooping cough (pertussis), polio, Hib, hepatitis B · Meningococcal group B · Rotavirus gastroenteritis | 2-month vaccines → |
| 12 weeks | 6-in-1 (dose 2) · PCV (dose 1) · Rotavirus oral (dose 2) | As above (2nd dose) · Pneumococcal disease (13 strains) · Rotavirus (2nd dose) | 4-month vaccines → |
| 16 weeks | 6-in-1 (dose 3) · MenB (dose 2) | As above (primary course complete) · MenB 2nd dose (primary course) | 4-month vaccines → |
| 12–13 months | Hib/MenC · MMR (dose 1) · PCV booster · MenB booster (dose 3) | Haemophilus influenzae type b + meningococcal C · Measles, mumps, rubella · Pneumococcal booster · MenB booster | 12-month vaccines → |
| 2–3 years (autumn each year) | Nasal flu spray (LAIV) | Influenza — current season strains (annual vaccination) | 2-year vaccines → |
| 3 years 4 months | MMR (dose 2) · 4-in-1 booster (DTaP/IPV) | Measles, mumps, rubella (2nd dose — near-complete protection) · Diphtheria, tetanus, whooping cough, polio (booster) | 3-year vaccines → |
| Reception–Year 11 (each autumn) | Nasal flu spray (LAIV) — school-delivered | Influenza — current season strains (annual vaccination, school programme) | 4-year vaccines → |
| Year 8 (age 12–13) | HPV vaccine (Gardasil 9) — dose 1, then dose 2 at 6–12 months | Human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, 58 — preventing cervical, anal, head/neck, and other HPV-related cancers plus genital warts | School vaccination programme |
| Year 9 (age 13–14) | Td/IPV (3-in-1 booster) · MenACWY | Tetanus, diphtheria, polio (adolescent booster) · Meningococcal groups A, C, W, Y | School vaccination programme |
Why the Schedule Is Timed the Way It Is — The Immunological Logic
The schedule is not arbitrary. Every interval, every age, every number of doses is based on the immunology of the developing infant immune system and the epidemiology of each disease. Understanding these principles is the most durable defence against misinformation.
Why Vaccines Start at 8 Weeks — Not Earlier, Not Later
Babies receive maternal IgG antibodies across the placenta during the third trimester of pregnancy. These provide passive immunity — protection borrowed from the mother, not actively generated by the baby. At birth, a term baby has maternal antibody levels comparable to the mother's. But these antibodies have a half-life of approximately 21–28 days and decline steadily from birth.
The problem with vaccinating before 8 weeks: circulating maternal antibodies partially neutralise vaccines targeting the same pathogens — particularly measles (which is why MMR is not given at 8 weeks). Vaccinating while maternal antibody levels are still high produces a blunted immune response, wasting the dose. The 8-week timing represents the point at which maternal antibodies have declined far enough for the 6-in-1 components to generate an effective active immune response.
Why not wait until 12 or 16 weeks? Because whooping cough (pertussis) is most dangerous in the first weeks of life — infants under 3 months who contract pertussis have the highest mortality and hospitalisation rates. Maternal antibodies from pertussis vaccination in pregnancy provide some bridge protection, but there is a gap. Starting the primary course at 8 weeks is specifically timed to close that gap as early as the immune system can respond effectively.
Why 3 Doses at 4-Week Intervals — Not 1, Not 2, Not 6 Weeks Apart
Each dose in the primary course drives a distinct immunological step:
- Dose 1 (8 weeks) — primary response: antigen-presenting cells (dendritic cells) process the vaccine antigens; T cells and B cells are activated; mostly IgM antibodies are produced initially; germinal centres in lymph nodes begin forming; the response is relatively modest at this first exposure
- Dose 2 (12 weeks) — affinity maturation: within germinal centres, B cells undergo somatic hypermutation of their antibody-binding sites; those that produce higher-affinity antibodies are selected for survival (Darwinian selection within the lymph node); class switching from IgM to IgG occurs; IgG antibodies are longer-lived and cross the placenta (protecting future pregnancies). The 4-week interval is the minimum required for this germinal centre reaction to complete — shorter intervals interrupt the process
- Dose 3 (16 weeks) — memory consolidation: memory B cells formed in germinal centres are further expanded; long-lived plasma cells migrate to the bone marrow where they can produce antibodies for years without further stimulation; memory T cells are consolidated. This is the dose that confers durability — the protection that persists for years after vaccination
Why the 1-Year Booster Produces Much Stronger Immunity
The primary course at 8–16 weeks is completed in the presence of residual maternal antibodies (though declining) and in a very immature immune system. The 1-year booster at 12–13 months re-exposes memory B and T cells generated by the primary course to the same antigens — but now:
- Maternal antibodies are completely cleared — the vaccine response is not attenuated
- Memory B cells respond within 1–3 days rather than 7–14 days (compared to the primary response)
- The anamnestic (recall) response produces antibody titres 10–100 times higher than the primary course — the key reason why immunity after a booster is qualitatively stronger, not just quantitatively higher
- The 8-month gap between the primary course and the 1-year booster (rather than a shorter interval) allows memory cells to fully mature and differentiate — a longer rest produces a stronger booster response than a shorter one
Why Some Immunity Lasts Decades and Some Lasts One Season
| Disease / Vaccine | Duration of Protection | The Reason |
|---|---|---|
| Measles (MMR) | Lifelong after 2 doses in most people | Measles virus is antigenically stable — it has not significantly mutated in decades. Antibodies targeting its surface proteins remain effective indefinitely. Long-lived plasma cells established by the 2-dose course produce measles-neutralising antibodies in the bone marrow for life. |
| Tetanus, diphtheria, polio | Decades — with periodic boosters | Antigenically stable pathogens; long-lived plasma cell populations established by the primary course. Boosters in adolescence (Year 9) and adulthood (after injury in some cases) top up antibody levels rather than restarting protection. |
| Whooping cough (pertussis) | 3–5 years — fastest-waning of all primary course vaccines | Acellular pertussis vaccine (the P in the 6-in-1 and 4-in-1) contains only purified toxin proteins, not whole bacteria. The purified protein components generate a narrower B-cell and T-cell response than natural infection, and memory declines faster. Whole-cell pertussis vaccines provided longer-lasting immunity but were withdrawn due to reactogenicity. Waning pertussis immunity is the primary reason for the pre-school booster and the pertussis vaccine in pregnancy. |
| Haemophilus influenzae type b (Hib) | Long-lasting after primary course + booster | Conjugate vaccine (Hib protein linked to a carrier protein) generates T-cell-dependent immunity and robust memory, unlike older polysaccharide vaccines. The 1-year Hib/MenC booster consolidates this. |
| Influenza (LAIV / injected) | One flu season — annual vaccination required | Influenza virus undergoes antigenic drift — the haemagglutinin (H) and neuraminidase (N) surface proteins mutate continuously. Each season's vaccine contains different strains selected by the WHO in February. Last year's antibodies do not adequately neutralise this year's mutated strains. Both antibody levels and viral strains change annually, making annual revaccination necessary. |
| HPV (Gardasil 9) | At least 10+ years confirmed; likely lifelong (ongoing studies) | HPV is antigenically stable; the virus-like particles in the vaccine generate very high antibody titres. Studies up to 15+ years show sustained protection with no evidence of significant waning. The 2-dose schedule at age 12-13 generates higher initial titres than 3-dose schedules in older recipients, providing a larger immunological reserve against waning. |
Why Each Vaccine Arrives at Its Specific Age
Why MenB Is Given at 8, 16 Weeks and 1 Year — and Not as a Single Dose
Meningococcal group B (MenB) uses an outer membrane protein vaccine (Bexsero) rather than a polysaccharide or conjugate vaccine. It generates a strong response but requires a 3-dose schedule in infancy because the components of Bexsero generate partly independent immune responses — 3 doses are needed to build comprehensive coverage against the varied MenB strains circulating in the population. The 1-year booster provides the final immunological consolidation as maternal antibodies have fully cleared.
Why the Pre-School Booster Is at 3 Years 4 Months — Not at 3 Years or 4 Years
The timing is a balance between two factors: whooping cough waning and school entry. By 3 years 4 months, it has been approximately 3 years since the 16-week pertussis dose — the most critical waning period for the fastest-waning component of the primary course. The timing is also specifically designed so that children complete the booster before entering primary school — where close classroom contact significantly raises the risk of pertussis transmission. The exact age of 3 years 4 months was chosen to precede the September school entry for virtually all children regardless of birthday.
Why HPV Vaccination at 12–13 (Year 8) Outperforms Later Vaccination
Three distinct advantages to the Year 8 timing:
- Higher immunogenicity at 12–13: The antibody response to HPV vaccination peaks in early adolescence — the titres generated at 12–13 are significantly higher than those generated at 16–18. At 12–13, a 2-dose schedule achieves the same or better protection as 3 doses at 15+. The immune system at this age is particularly responsive to subunit vaccines.
- Pre-exposure timing: HPV is sexually transmitted. The Year 8 vaccination precedes the onset of sexual activity for the overwhelming majority of recipients. Vaccination after exposure to HPV strains still provides protection against other strains, but the maximum cancer-prevention benefit requires pre-exposure vaccination.
- Gender-neutral since 2019: HPV vaccination in the UK has been offered to both boys and girls since 2019 (extended from girls-only), providing direct protection against HPV-related cancers in males (oropharyngeal, anal) and contributing to herd protection.
Why MenACWY at Year 9 and Not in Infancy
Adolescence (age 15–24) is the period of highest meningococcal carriage — the proportion of people asymptomatically carrying Neisseria meningitidis in the nasopharynx peaks in young adults. Vaccination at Year 9 targets recipients just before they enter the highest-carriage age group and before university or sixth-form mixing — both settings associated with meningococcal disease clusters.
The A, C, W, and Y strains covered by MenACWY are different from the MenB strain covered in infancy; the two vaccines target different meningococcal serogroups. The 1-year Hib/MenC already covers meningococcal C — the Year 9 MenACWY covers the additional strains (A, W, Y) relevant to the adolescent and young adult epidemiology.
Herd Immunity Thresholds — Why Coverage Matters for Everyone
Herd immunity does not mean that everyone in the population is protected individually. It means that vaccination coverage is high enough that a pathogen cannot sustain transmission chains — each infectious person, on average, infects fewer than 1 additional person, causing the outbreak to die out.
The threshold depends on how contagious the disease is (its basic reproduction number, R₀). More contagious diseases require higher vaccination coverage to achieve herd protection:
| Disease | Herd Immunity Threshold | UK 2-Dose MMR Coverage (approximate) | Current Status |
|---|---|---|---|
| Measles | ~95% of population immune | ~86–90% (below threshold in many areas) | ⚠️ Below herd immunity threshold nationally — localised outbreaks possible |
| Whooping cough (pertussis) | ~92–94% | Primary course coverage ~92–93%; some waning reduces effective coverage | ⚠️ Cyclical outbreaks every 3–4 years reflecting waning immunity |
| Polio | ~80–85% | ~92–95% primary course coverage | ✅ Well above threshold; polio eliminated in UK |
| Diphtheria | ~85% | ~92–95% primary course coverage | ✅ Very rare in UK — last indigenous case 1986 |
| Mumps | ~85–90% | ~86–90% | ⚠️ Outbreaks occur in incompletely vaccinated cohorts including university students |
| MenB | N/A — direct protection primary (herd immunity not primary mechanism) | ~93% at 12 months (3-dose course) | ✅ MenB cases have fallen significantly since 2015 introduction |
What's Not in the UK Routine Schedule — And Why
The UK schedule is evidence-based and regularly reviewed by the JCVI. Several vaccines available elsewhere are not in the routine UK programme — not because they are unsafe or ineffective, but because the population-level analysis of benefit, cost, and unintended consequences led to different conclusions for the UK population.
| Vaccine | Used Where | Why Not in UK Routine Schedule | UK Availability |
|---|---|---|---|
| Chickenpox (varicella) | US, Canada, Australia, most of EU, Japan | Universal childhood vaccination would reduce wild-type VZV circulation, eliminating the natural immune boosting that suppresses VZV reactivation in adults. Population-level modelling suggested this would increase shingles (herpes zoster) rates in adults aged 50–70 during the post-introduction period — a significant burden given shingles affects ~25% of people in their lifetime. This is a population-level calculation, not a statement about individual vaccine safety. | Available privately at any age from 12 months; 2 doses required from age 9 months; ~£60–90 per dose |
| Hepatitis B (birth dose) | US, Canada, Australia, most of EU | The UK 6-in-1 vaccine (introduced in 2017) includes hepatitis B, providing the primary course at 8/12/16 weeks. A birth dose (as given elsewhere) targets mother-to-child transmission, which the UK addresses through targeted hepatitis B screening of all pregnant women and birth-dose + immunoglobulin for babies of HBsAg-positive mothers. The UK's comprehensive antenatal screening programme achieves similar protection for high-risk newborns without a universal birth dose. | Given at birth to babies born to HBsAg-positive mothers; routine 6-in-1 covers hepatitis B from 8 weeks |
| Hepatitis A | US (routine 2-dose schedule from 12 months), Israel | Hepatitis A incidence in the UK is low; transmission is primarily through contaminated food/water or travel. Universal childhood vaccination is not cost-effective in the UK context. Targeted vaccination for high-risk groups (travellers to endemic areas, men who have sex with men, people with chronic liver disease) is provided. | Available on NHS for high-risk individuals; available privately for all travellers to endemic areas; combined hepatitis A+B vaccine available |
| Rotavirus (after 15 weeks) | Ongoing in UK up to 24 weeks in US schedule | Rotavirus vaccine in the UK is only given at 8 and 12 weeks (completed by 24 weeks). The rotavirus vaccine contains live attenuated virus — an age restriction applies because the risk of intussusception (bowel obstruction) from the live vaccine is age-related and increases if the first dose is given after 15 weeks. This is not a UK-specific restriction; it applies globally to the live rotavirus vaccines. | Completed at 8 and 12 weeks; no catch-up available after 24 weeks because of intussusception risk |
| Meningococcal B (adults) | Some country programmes offer to adolescents | MenB vaccine (Bexsero) is in the UK infant schedule. Adolescent MenB vaccination has not been added to the routine programme; the JCVI has reviewed but cost-effectiveness modelling at current vaccine prices has not supported routine adolescent extension. Available privately and recommended for university students in some guidance. | Available privately; some universities recommend it for students moving into halls |
"Too Many Vaccines Too Soon" — What the Immune System Actually Does
The concern that infants receive too many vaccines too soon — and that this overwhelms or damages the immune system — is the most common vaccine-related concern parents raise. It is immunologically testable, and has been tested.
The human immune system at birth is capable of generating immune responses to thousands of antigens simultaneously. This is not theoretical — it is necessary for survival. A term newborn exits a near-sterile intrauterine environment into a world populated by trillions of bacteria and millions of potential pathogens. Within hours of birth, the infant's skin, gut, and airways are colonised by thousands of bacterial species — each presenting multiple antigens, each requiring an immune response to maintain homeostasis. The immune system manages this continuously from the moment of delivery.
The NHS 8-week vaccination visit introduces antigens from 6 diseases in the 6-in-1, antigens from MenB, and a live attenuated rotavirus. The total number of distinct antigens across all three vaccines at the 8-week visit is approximately 25–30 proteins.
A single respiratory viral infection — a common cold, rhinovirus — exposes the immune system to hundreds of viral proteins simultaneously. The immune system manages both the vaccine antigens and the rhinovirus without competition or impairment to either response.
Catch-Up Schedules — If Appointments Were Missed
No NHS childhood vaccine has an upper age cut-off — all can be given at any age if not previously received. Catch-up schedules are arranged through the GP surgery.
| Missed Vaccine | Catch-Up Approach | Notes |
|---|---|---|
| 6-in-1 primary course (partially or fully missed) | Contact GP surgery for a vaccination review; complete remaining doses with minimum 4-week intervals | The total primary course is 3 doses regardless of age; if 0 doses given, all 3 are still needed; if 1 or 2 doses given, complete remaining doses from where the child left off |
| MenB (partially or fully missed) | Contact GP; complete remaining doses | 3-dose course in infancy; the schedule adjusts if starting later; discuss with GP |
| Rotavirus (missed) | No catch-up after 24 weeks of age | The live rotavirus vaccine has an absolute age restriction because of age-related intussusception risk; first dose must be before 15 weeks; course must be completed before 24 weeks; there is no catch-up option after 24 weeks |
| 1-year vaccines (Hib/MenC, MMR, PCV, MenB booster) missed | Contact GP — give all four at any age | All can be given simultaneously as separate injections or on the same day; no catch-up time limit |
| Pre-school booster (3y4m) missed | Contact GP — give MMR 2nd dose and 4-in-1 at any age | MMR 2nd dose is particularly important to complete before school entry; 4-in-1 can be given at any age; minimum 4 weeks between MMR doses 1 and 2 |
| HPV missed at Year 8 | Contact school vaccination service or GP; available through school or GP for eligible cohort | NHS-funded HPV vaccine is offered to all school-age children up to age 25 in England who missed the routine Year 8 offer; contact the local school vaccination service to arrange |
| MenACWY missed at Year 9 | Contact GP or school vaccination service | NHS-funded MenACWY is available for those who missed the routine Year 9 offer up to age 25 in England; contact GP or school vaccination service |
To check which vaccines have been recorded: contact your GP surgery and ask for a vaccination review appointment. The surgery can access the NHS immunisation record and identify any gaps. Keeping your own record (red book and a vaccination app) provides a second source of truth, particularly if you have moved between GP surgeries or lived abroad.
The Complete Vaccination Series — Deep Guides by Age
Each article in the Lunara vaccination series covers one age window in depth — the specific vaccines, the clinical detail, what to expect, and the strategic health information relevant at that age.
Newborn & 8-Week Vaccines →
The first appointment at 8 weeks: why it's the most feared and the most protective. What happens in the hour after; fever patterns; the proactive paracetamol rule for MenB; and how vaccinated babies react to the 6-in-1 vs. the MenB.
4-Month Vaccines →
Completing the primary course at 12 and 16 weeks. Why the 3rd dose matters more than the 1st. The MenB 2nd dose — why there's no proactive paracetamol at 16 weeks. Rotavirus: what to expect in the nappy in the week after the oral vaccine.
12-Month Vaccines →
The 1-year booster: the most loaded appointment in the schedule — 4 vaccines on the same day. The MMR delayed reaction profile (fever days 6–10, rash days 7–12). The proactive paracetamol rule for MenB at 1 year specifically. The day-by-day guide.
2-Year Vaccines →
The nasal flu spray starts. First routine annual vaccine. First vaccine given as a nasal spray rather than an injection. Why LAIV is 30–50% more effective than injected flu vaccine in children. Why it cannot give flu. The contraindications parents need to know.
3-Year Vaccines (Pre-School Booster) →
The pre-school booster at 3 years 4 months — the first injection a child is old enough to understand, anticipate, and dread. Preparing a verbal child. EMLA cream application guide. The MMR delayed reaction when the child is now frightened, not just uncomfortable. The school vaccination roadmap to Year 9.
4-Year Vaccines (School Flu Spray) →
The first vaccine without a parent in the room. How Reception school flu spray is delivered. Preparing a 4-year-old for a vaccine without you present. The NCMP height and weight letter — what the BMI classification means and doesn't mean. Vision screening at school entry.
5-Year Vaccines (Chickenpox Guide) →
No injection at 5 years. But chickenpox peaks in Year 1. The medication guide — ibuprofen's specific NHS caution in chickenpox (most parents don't know this). The school exclusion rule that is applied incorrectly constantly. Bacterial complication red flags. Urgent guidance for pregnant and immunocompromised household contacts.
Frequently Asked Questions — Complete UK Vaccination Schedule
8 weeks: 6-in-1 (diphtheria, tetanus, whooping cough, polio, Hib, hepatitis B), MenB, rotavirus. 12 weeks: 6-in-1 2nd dose, PCV, rotavirus 2nd dose. 16 weeks: 6-in-1 3rd dose, MenB 2nd dose. 12–13 months: Hib/MenC, MMR 1st dose, PCV booster, MenB booster. 2-3 years and annually: nasal flu spray (LAIV). 3 years 4 months: MMR 2nd dose, 4-in-1 pre-school booster. Reception–Year 11 annually: school-delivered flu spray. Year 8: HPV vaccine (2 doses). Year 9: Td/IPV booster, MenACWY.
Two reasons: maternal antibodies and disease risk. Maternal antibodies transferred across the placenta partially neutralise vaccines given too early, blunting the immune response. By 8 weeks, maternal antibodies have declined enough for effective active vaccination. Simultaneously, whooping cough is most dangerous in the first months of life — starting the primary course at 8 weeks closes the gap between waning maternal pertussis antibodies and the baby's own vaccine-generated protection as early as the immune system can effectively respond.
Each dose drives a distinct immunological step that requires the full 4-week interval to complete: dose 1 generates the initial B-cell response; dose 2 triggers affinity maturation (selecting higher-quality antibody-producing cells in germinal centres — the 4-week gap is the minimum needed for this process); dose 3 consolidates memory B cells and establishes long-lived plasma cells in the bone marrow that produce antibodies for years. Shorter intervals between doses interrupt these processes. Two doses produce incomplete memory; one dose produces only a primary response without long-term consolidation.
The NHS does not recommend it. Delaying extends the unprotected window for diseases that are most dangerous in young infancy — particularly whooping cough in the first months of life. The minimum effective dose intervals (4 weeks for the primary course) are immunologically based: shorter intervals don't work, but longer intervals only extend vulnerability. Spreading vaccines across more appointments does not reduce the total antigen load — it simply delays protection against each disease. If you have concerns, discuss with your GP, who can address them specifically for your child's circumstances.
No — it does not reflect how the immune system works. A newborn's immune system manages thousands of new bacterial and viral antigens simultaneously from the moment of birth. The NHS schedule introduces approximately 25–30 antigens at the 8-week visit — a single common cold exposes the immune system to hundreds of viral proteins simultaneously. The schedule is designed to use the minimum effective antigen load; each generation of combined vaccines (replacing older separate vaccines) uses fewer antigens per dose. The concern was formally examined by Offit et al. (2002) and found no immunological basis.
The JCVI's decision is based on population-level shingles modelling. Universal childhood vaccination would reduce circulating wild-type VZV — eliminating the natural immune boosting that adults receive from exposure to chickenpox in children around them. This boosting suppresses VZV reactivation as shingles in adults. Without it, shingles rates in the 50–70 age group were projected to increase significantly during the transition period following universal childhood vaccination. This is a population-level modelling decision, not a statement that the chickenpox vaccine is unsafe. It remains available privately at any age from 12 months.
Contact your GP surgery and ask for a vaccination review. No NHS childhood vaccine has an upper age cut-off — all can be given at any age. The surgery can check which vaccines are recorded as given and arrange any outstanding. Exception: rotavirus vaccine cannot be given after 24 weeks of age (age-related intussusception risk with the live vaccine). For HPV and MenACWY missed from the school programme, NHS-funded catch-up is available up to age 25 in England — contact the local school vaccination service or GP.
Because the influenza virus mutates continuously — a process called antigenic drift. The surface proteins (particularly haemagglutinin and neuraminidase) that antibodies target change from season to season. Each year the WHO analyses which influenza strains are circulating globally and selects the strains for that season's vaccine. The 2025-26 vaccine contains different strains from the 2024-25 vaccine. Last year's antibodies don't adequately neutralise this year's mutated strains — both the virus and antibody levels change annually. By contrast, measles virus is antigenically stable; antibodies from MMR vaccination decades ago still neutralise current measles strains.
The UK schedule is broadly similar to Western European countries but with notable differences. UK-specific additions: MenB in infancy (Bexsero) — UK was among the first countries to introduce this; LAIV nasal flu spray for children rather than injected flu vaccine. Differences from US/Australia: no routine chickenpox (varicella) vaccine; no routine hepatitis A; no hepatitis B birth dose (the 6-in-1 covers hepatitis B from 8 weeks). Similar to most of Europe: HPV vaccination in early adolescence; pertussis-containing booster in pregnancy. The hepatitis B component was added to the UK 6-in-1 in 2017 — the UK was later than most countries in including hepatitis B in the primary course.
Knowing Why Makes the Schedule More Than a Calendar
The vaccination schedule is often presented as a series of dates — 8 weeks, 12 weeks, 1 year — without any explanation of the biology beneath. A list of dates is easy to follow but easy to doubt. "Why 3 doses? Why not wait a bit longer? Why does my child need the flu vaccine every year when the MMR only needs to be given twice?" These are reasonable questions. The answers are in the immune system.
Every interval in the schedule is the minimum effective interval. Every booster dose drives a qualitatively stronger immune response than the primary course. Every age — 8 weeks, 3 years 4 months, Year 8 — is chosen because that specific window offers the best balance of immune readiness and disease risk.
The schedule is not asking parents to trust without understanding. The understanding is available. This article is one place to find it.
One place for the complete vaccination record —
from the 8-week appointment to Year 9 and beyond.
Lunara tracks every NHS appointment, every dose, every annual flu spray, and every school vaccination — across every year of the schedule. When the Year 8 HPV consent form arrives, the complete history since the first 6-in-1 is already there. When you change GP surgeries, nothing is lost. When a health visitor asks about the vaccination record, you can show it. Free to start.